Overview

First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-539, a menin-MLL(KMT2A) inhibitor, in patients with refractory or relapsed acute myeloid leukemia (AML).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Kura Oncology, Inc.